SAGE - Sage Therapeutics, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
Cambridge,
United States
Type: Equity
SAGE price evolution
SAGE
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $101.23 | $175.49 | $72.32 | |
| Short term investments | $546.89 | $544.36 | $682.19 | |
| Net receivables | $18.07 | $9.94 | $10.51 | $83.01 |
| Inventory | ||||
| Total current assets | $604.99 | $686.81 | $755.44 | $869.35 |
| Long term investments | ||||
| Property, plant & equipment | $12.27 | $2.49 | $4.44 | $6.38 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $10.29 | $12.16 | $12.93 | |
| Total investments | $546.89 | $544.36 | $682.19 | |
| Total assets | $622.43 | $697.11 | $767.6 | $882.28 |
| Current liabilities | ||||
| Accounts payable | $7.13 | $8.65 | $6.48 | $10.32 |
| Deferred revenue | ||||
| Short long term debt | $1.41 | $3.31 | $5.17 | |
| Total current liabilities | $60.41 | $69.04 | $61.8 | $82.75 |
| Long term debt | ||||
| Total noncurrent liabilities | ||||
| Total debt | $1.41 | $3.31 | $5.17 | |
| Total liabilities | $70.6 | $69.04 | $61.8 | $82.75 |
| Shareholders' equity | ||||
| Retained earnings | -$2874.55 | -$2781 | -$2678.14 | -$2569.66 |
| Other shareholder equity | $0.9 | -$0.69 | -$0.79 | -$0.81 |
| Total shareholder equity | $628.06 | $705.8 | $799.53 | |
| (in millions $) | 31 Dec 2023 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $72.32 | $163.97 | $295.5 | $1662.8 |
| Short term investments | $682.19 | $1109.79 | $1448.06 | $438.47 |
| Net receivables | $83.01 | $13.66 | $18.51 | |
| Inventory | $1.5 | |||
| Total current assets | $869.35 | $1336.98 | $1800.64 | $2122.37 |
| Long term investments | ||||
| Property, plant & equipment | $6.38 | $13.43 | $19.13 | $31.82 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $12.93 | $19.47 | $24.64 | $36.88 |
| Total investments | $682.19 | $1109.79 | $1448.06 | $438.47 |
| Total assets | $882.28 | $1356.45 | $1825.29 | $2159.25 |
| Current liabilities | ||||
| Accounts payable | $10.32 | $18.95 | $10.45 | $3.69 |
| Deferred revenue | ||||
| Short long term debt | $5.17 | $7.64 | $7.47 | $8.66 |
| Total current liabilities | $82.75 | $99.26 | $85.19 | $67.2 |
| Long term debt | $4.49 | $10.96 | $19.44 | |
| Total noncurrent liabilities | $4.59 | $11.06 | $19.71 | |
| Total debt | $5.17 | $12.13 | $18.43 | $28.1 |
| Total liabilities | $82.75 | $103.85 | $96.26 | $86.91 |
| Shareholders' equity | ||||
| Retained earnings | -$2569.66 | -$2028.17 | -$1495.39 | -$1037.49 |
| Other shareholder equity | -$0.81 | -$10.21 | -$2.66 | $0.41 |
| Total shareholder equity | $799.53 | $1252.6 | $1729.03 | $2072.33 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $11.87 | $8.65 | $7.9 | $77.97 |
| Cost of revenue | $1.41 | $1.27 | $0.82 | |
| Gross Profit | $6.59 | $7.25 | $6.63 | $77.15 |
| Operating activities | ||||
| Research & development | $62.56 | $71.73 | $64.33 | |
| Selling, general & administrative | $55.98 | $52.57 | $55.11 | |
| Total operating expenses | $107.79 | $118.55 | $124.31 | $119.23 |
| Operating income | -$111.3 | -$117.67 | -$42.07 | |
| Income from continuing operations | ||||
| EBIT | -$102.85 | -$108.48 | -$32.71 | |
| Income tax expense | ||||
| Interest expense | $7.64 | |||
| Net income | ||||
| Net income | -$93.55 | -$102.85 | -$108.48 | -$32.71 |
| Income (for common shares) | -$102.85 | -$108.48 | -$32.71 | |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $86.45 | $7.69 | $6.31 | $1114.2 |
| Cost of revenue | $2.16 | $0.81 | $0.55 | $0.56 |
| Gross Profit | $84.3 | $6.87 | $5.75 | $1113.63 |
| Operating activities | ||||
| Research & development | $356.24 | $326.16 | $283.17 | $292.71 |
| Selling, general & administrative | $274.52 | $227.7 | $183.5 | $196.95 |
| Total operating expenses | $664.14 | $553.86 | $466.66 | $517.41 |
| Operating income | -$579.85 | -$546.99 | -$460.91 | $596.23 |
| Income from continuing operations | ||||
| EBIT | -$541.49 | -$532.78 | -$457.89 | $606.07 |
| Income tax expense | ||||
| Interest expense | ||||
| Net income | ||||
| Net income | -$541.49 | -$532.78 | -$457.89 | $606.07 |
| Income (for common shares) | -$541.49 | -$532.78 | -$457.89 | $606.07 |
| (in millions $) | 30 Oct 2024 | 30 Jun 2024 | 31 Mar 2024 | 31 Dec 2023 |
|---|---|---|---|---|
| Net income | -$102.85 | -$108.48 | -$32.71 | |
| Operating activities | ||||
| Depreciation | $0.31 | $0.34 | $0.41 | |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $17.17 | $13.7 | $12.95 | |
| Total cash flows from operations | -$80.44 | -$37.83 | -$119.52 | |
| Investing activities | ||||
| Capital expenditures | $0.11 | |||
| Investments | -$0.39 | $139.44 | $41.95 | |
| Total cash flows from investing | $220.1 | -$0.39 | $139.44 | $42.06 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $8.19 | $1.56 | ||
| Net borrowings | ||||
| Total cash flows from financing | $10.66 | $8.07 | $1.56 | -$0.26 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | $30.14 | -$72.75 | $103.16 | -$77.72 |
| (in millions $) | 31 Dec 2023 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | -$541.49 | -$532.78 | -$457.89 | $606.07 |
| Operating activities | ||||
| Depreciation | $1.39 | $1.12 | $4.18 | $2.63 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $73.37 | $61.6 | $104.63 | $95.99 |
| Total cash flows from operations | -$540.59 | -$460.04 | -$378.18 | $664.28 |
| Investing activities | ||||
| Capital expenditures | -$0.55 | -$0.94 | -$0.37 | -$0.34 |
| Investments | $443.47 | $326.37 | -$1002.08 | $443.03 |
| Total cash flows from investing | $442.91 | $325.43 | -$1002.45 | $442.68 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $6.93 | $3.11 | $14.72 | $426.76 |
| Net borrowings | ||||
| Total cash flows from financing | $6.03 | $3.07 | $13.33 | $426.76 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$91.64 | -$131.53 | -$1367.3 | $1533.73 |
News
Fundamentals
| Market cap | $390.90M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 61.17M |
| Revenue | $106.40M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$337.59M |
| Revenue Q/Q | 337.08% |
| Revenue Y/Y | 837.52% |
| P/E ratio | -1.16 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 3.67 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | N/A |
| EPS | -$5.52 |
|---|---|
| ROA | -45.48% |
| ROE | N/A |
| Debt/Equity | 0.10 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 10.02 |
| Quick ratio | N/A |